UroToday

Non-Muscle Invasive Bladder Cancer

Tullika Garg discusses treatment burden and a goal elicitation communication tool for older adults with non-muscle invasive bladder cancer. High-risk NMIBC can require up to 19 or ...
UroToday

The Latest Research on Biochemical Recurrence Prostate Cancer

Overview on the use of androgen deprivation therapy (ADT) added to salvage radiation therapy (SRT) for prostate cancer patients with biochemical recurrence after prostatectomy. Th ...
UroToday

Salvage prostatectomy for locally recurrent prostate cancer after radiation: a narrative review of indications, outcomes, and surgical advancements.

Salvage prostatectomy (sRP) is one of several treatment options for localized prostate cancer recurrence after radiation. However, given the complexity of this operation, traditionally high ...
UroToday

Outcomes of Patients With Favorable Intermediate Risk Gleason Grade Group 2 Prostate Cancer Undergoing Radical Prostatectomy in the MRI Era: Refining Active Surveillance ...

While guidelines state that patients with NCCN favorable intermediate risk (FIR) prostate cancer (PCa) may consider active surveillance (AS), there is a relative lack of longer term follow up data ...
UroToday

Top advances of the year: Radiopharmaceutical therapy for prostate cancer.

Radiopharmaceutical therapy, a form of targeted radionuclide therapy, has emerged as a rapidly advancing area in prostate cancer management, with significant developments in 2025. The field, which ...
UroToday

PROQURE-I: a phase I study adding concurrent [177Lu]Lu-PSMA-617 to EBRT and ADT in curative intent treatment of N1 prostate cancer.

Current treatment of N1M0 prostate cancer (PCa) with locoregional external beam radiotherapy (EBRT) and long-term androgen deprivation therapy (ADT) has suboptimal five-year recurrence-free rates.
UroToday

Alternative Boost Approaches in Radiation Therapy IRreversible Electroporation Versus RADIAtioN BoosT for Intermediate Risk Prostate Cancer (IRRADIANT)

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
UroToday

CHHiP Trial Evaluates a Multimodal AI Biomarker in Localized Prostate Cancer - Anna Wilkins

Anna Wilkins describes her validation of the Artera MMAI biomarker, drawing on over 2,000 biopsies from the 3,200-patient CHHiP radiotherapy fractionation trial in localized prostate cancer. The MMAI ...
UroToday

Characterization of Clinically Significant Prostate Cancer in the Peripheral Zone Using Rapid B1-Insensitive MR Fingerprinting.

Background MR fingerprinting (MRF) has shown utility in focal prostate lesion characterization as a complement to standard prostate MRI. Purpose To determine the utility of a rapid, B1-insensitive MRF ...
UroToday

First-in-Human Combination of Lead-212-Labeled PSMA Radioligand Therapy and Metabotropic Glutamate Receptor Inhibitor Riluzole as Radiosensitizer in Metastatic Castration ...

We present the first metastatic castration-resistant prostate cancer (mCRPC) patient, heavily pretreated with multiple systemic and radioligand therapies, who received [212Pb]Pb-PSMA radioligand ...
UroToday

GUNS Trial Examines Biomarker‑Selected Neoadjuvant Approaches in High‑Risk Prostate Cancer - Martin Gleave

Matthew Cooperberg speaks with Martin Gleave about GUNS, a neoadjuvant adaptive umbrella trial for men with high-volume, high-grade prostate cancer. Now at 280 patients enrolled, GUNS sequences needle ...
UroToday

Phase 3 INDICATE Trial for Patients with Biochemically Recurrent Prostate Cancer - Neha Vapiwala

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.